In estrogen receptor–positive (ER + ) and human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancers, ribociclib, palbocilib, and abemaciclib significantly improve survival outcomes in patients13. Here, ERBB2 is linked to breast carcinoma.